Frequently Asked Questions

The goals of the registry are to rapidly define the impact of COVID-19 on patients with psoriasis and determine how factors such as age, comorbidities, and psoriasis treatments impact COVID outcomes.

The data will be shared:

1. Directly on the website covidpso.org
2. Through listservs and social media
3. Via scholarly publications. We plan to update the website frequently, with reports including number of cases (and COVID outcomes) by country, number of cases by treatment, etc.

We have created a registry that contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.The Wake Forest Institutional Review Board has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

Our database system (REDCap) provides for secure web-based data entry with the data stored on secure servers at Wake Forest University. All data is encrypted during transmission. The web and database servers are monitored by the IT staff, patched frequently, and scanned by a third party vendor to ensure that they are protected against known vulnerabilities. Access is by individual user id, and is restricted to the forms and/or functions that the user needs to have.

If you have a patient with psoriasis and confirmed SARS-CoV-2/COVID-19 testing, please complete the form after the patient has had COVID-19 for a long enough duration to experience partial or complete recovery, hospitalization, or death. If the patient’s clinical status changes after a form has been completed, please refer to question #5.

Once a survey has been submitted, it cannot be re-accessed or edited at a later time. However, if you have updated information or any changes since you have reported a case, please re-report the case and email COVID_PSO@wakehealth.edu to ask our team to remove the duplicate entry.

Health care providers taking care of patients with psoriasis and documented COVID-19.

No, the Case Report Form is designed to be filled out by a health care provider. Patients with psoriasis and documented COVID 19 should encourage their health care provider to complete a Case Report Form on their behalf.

Thank you for your interest in helping with this international effort! Please consider asking your health care provider to report on our website if you or any of their psoriasis patients contract COVID-19. We encourage you to check our website frequently, as we will be posting data and updates at least weekly.

It will take approximately five minutes to complete the survey.

Yes. This is an international effort, and we encourage health care providers around the world to report to this registry.

Yes, we hope that this will produce sufficient data to inform care of psoriasis patients.

This is a collaborative, world-wide effort. With users reporting cases in real time, we hope to rapidly determine the impact of COVID-19 on patients with psoriasis and ascertain how medications, comorbidities, and demographic factors modulate their risk. As above, these data will be made available on our project website and frequently updated.

Please see the Updates and Data information below for updated reports, including number of cases (and COVID outcomes) by country, number of cases by treatment, etc.

This project is being led by Steven Feldman, MD, PhD (Professor of Dermatology) and William Huang, MD, MPH (Associate Professor of Dermatology) at Wake Forest School of Medicine in Winston-Salem, North Carolina.

Official partners include:

National Psoriasis Foundation

 

SECURE-AD | Covid19 Dermatology Registry

 

 

Please direct questions to COVID_PSO@wakehealth.edu.